Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Брентуксимаб ведотин в лечении рецидивов и рефрактерных форм лимфомы Ходжкина
Брентуксимаб ведотин в лечении рецидивов и рефрактерных форм лимфомы Ходжкина
Демина Е.А. Брентуксимаб ведотин в лечении рецидивов и рефрактерных форм лимфомы Ходжкина. Современная Онкология. 2016; 18 (2): 15–18.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Современное лечение лимфомы Ходжкина позволяет излечить около 80% больных независимо от стадии заболевания. Однако у 10–30% больных терапия 1-й линии оказывается недостаточно эффективной, и они нуждаются в продолжении лечения. Появление препаратов таргетного действия, специфичных для опухолевых клеток Березовского–Рид–Штернберга, открывает новые перспективы в лечении лимфомы Ходжкина. В статье приводится обзор исследований по применению нового препарата брентуксимаба ведотина при лечении рецидивов и рефрактерных форм лимфомы Ходжкина.
Ключевые слова: брентуксимаб ведотин, лимфома Ходжкина, лечение.
Key words: brentuximab vedotin, Hodgkin lymphoma, treatment.
Ключевые слова: брентуксимаб ведотин, лимфома Ходжкина, лечение.
________________________________________________
Key words: brentuximab vedotin, Hodgkin lymphoma, treatment.
Полный текст
Список литературы
1. De Vita VT. The consequences of the chemotherapy of Hodgkin’s disease: the 10th David A. Karnofsky memorial lecture. Cancer 1981; 47: 1–13.
2. Engert A, Younes A, editors. Hematologic malignancies: Hodgkin lymphoma. Second edition. A Comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg: Springer, 2015.
3. Horning S, Fanale M, deVos S et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol 2008; 19: 118(abstr).
4. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14.
5. Matsumoto K, Terakawa M, Miura K et al. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004; 172: 2186–93.
6. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764–9.
7. Forero-Torres A, Leonard JP, Younes A et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146: 171–9.
8. Dosio F, Brusa P, Cattel L. Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins 2011; 3: 848–83.
9. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 2003 102:1458-1465; published ahead of print April 24, 2003 10.1182/blood-2003-01-0039.
10. Kung MS, Sutherland, Sanderson RJ, Gordon KA et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*. J Biol Chem 2006; 281 (15): 10540–7. April 14, DOI 10.1074/jbc.M 510026200
11. Katz J, Janik JA, Yones A. Brentuximab vedotin (SGN-35). 2011 Clin Cancer Res 17: 6428–36.
12. Younes A, Gopal AK, Smith SE et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol 2012; 30: 2183–9.
13. Arai S, Fanale M, DeVos S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013; 54: 2531–33.
14. Gopal AK, Chen R, Smith SE et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125 (8): 1236–43.
15. Perrot A, Monjanel H, Bouabdallah R et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica 2014; 99 (s1), 498, abstr S1293.
16. Perrot A, Monjanel H, Bouabdallah R et al. Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica 2016; 101 (4): 466–73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14.
17. Majhail NS, Weisdorf DJ, Defor TE et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065–72.
18. Moskowitz CH, Paszkiewicz-Kozik E, Nadamanee A et al. Analisis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled sdudy of brentuximab vedotin consolidation after autologous stem cell transplant. Hematol Oncol 2015; 33: 165.
19. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. DOI: http://dx.doi.org/10.1016/S0140-6736(15)60165-9. Lancet, Vol. 385, No. 9980, p1853–1862 Published online: March 18, 2015.
20. Sweetenham JW, Walewski J, Nadamanee A et al. Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biol Blood Marrow Transplant 2016; 22: S19e-S481abstr 24.
21. Bonthapally V, Ma E, Viviani S et al. Healthcare utilization in the AETHERA trail: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT. Hematol Oncol 2015; 33: 193, abstr 177.
22. Kuruvilla J, Connors JM, Sawas A et al. A phase 1 study of brentuximab vedotin (BV) and bendamustine (B) in relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL). Hematol Oncol 2015; 33: 148, abstr 090.
23. Theurich S, Malcher J, Wennhold K et al. Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. JCO Feb 10, 2013: e59-e63; published online on December 26, 2012; 10.1200/JCO.2012.43.6832.
2. Engert A, Younes A, editors. Hematologic malignancies: Hodgkin lymphoma. Second edition. A Comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg: Springer, 2015.
3. Horning S, Fanale M, deVos S et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol 2008; 19: 118(abstr).
4. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14.
5. Matsumoto K, Terakawa M, Miura K et al. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004; 172: 2186–93.
6. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764–9.
7. Forero-Torres A, Leonard JP, Younes A et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146: 171–9.
8. Dosio F, Brusa P, Cattel L. Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins 2011; 3: 848–83.
9. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 2003 102:1458-1465; published ahead of print April 24, 2003 10.1182/blood-2003-01-0039.
10. Kung MS, Sutherland, Sanderson RJ, Gordon KA et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*. J Biol Chem 2006; 281 (15): 10540–7. April 14, DOI 10.1074/jbc.M 510026200
11. Katz J, Janik JA, Yones A. Brentuximab vedotin (SGN-35). 2011 Clin Cancer Res 17: 6428–36.
12. Younes A, Gopal AK, Smith SE et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol 2012; 30: 2183–9.
13. Arai S, Fanale M, DeVos S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013; 54: 2531–33.
14. Gopal AK, Chen R, Smith SE et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125 (8): 1236–43.
15. Perrot A, Monjanel H, Bouabdallah R et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica 2014; 99 (s1), 498, abstr S1293.
16. Perrot A, Monjanel H, Bouabdallah R et al. Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica 2016; 101 (4): 466–73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14.
17. Majhail NS, Weisdorf DJ, Defor TE et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065–72.
18. Moskowitz CH, Paszkiewicz-Kozik E, Nadamanee A et al. Analisis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled sdudy of brentuximab vedotin consolidation after autologous stem cell transplant. Hematol Oncol 2015; 33: 165.
19. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. DOI: http://dx.doi.org/10.1016/S0140-6736(15)60165-9. Lancet, Vol. 385, No. 9980, p1853–1862 Published online: March 18, 2015.
20. Sweetenham JW, Walewski J, Nadamanee A et al. Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biol Blood Marrow Transplant 2016; 22: S19e-S481abstr 24.
21. Bonthapally V, Ma E, Viviani S et al. Healthcare utilization in the AETHERA trail: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT. Hematol Oncol 2015; 33: 193, abstr 177.
22. Kuruvilla J, Connors JM, Sawas A et al. A phase 1 study of brentuximab vedotin (BV) and bendamustine (B) in relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL). Hematol Oncol 2015; 33: 148, abstr 090.
23. Theurich S, Malcher J, Wennhold K et al. Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. JCO Feb 10, 2013: e59-e63; published online on December 26, 2012; 10.1200/JCO.2012.43.6832.
2. Engert A, Younes A, editors. Hematologic malignancies: Hodgkin lymphoma. Second edition. A Comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg: Springer, 2015.
3. Horning S, Fanale M, deVos S et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol 2008; 19: 118(abstr).
4. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14.
5. Matsumoto K, Terakawa M, Miura K et al. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004; 172: 2186–93.
6. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764–9.
7. Forero-Torres A, Leonard JP, Younes A et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146: 171–9.
8. Dosio F, Brusa P, Cattel L. Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins 2011; 3: 848–83.
9. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 2003 102:1458-1465; published ahead of print April 24, 2003 10.1182/blood-2003-01-0039.
10. Kung MS, Sutherland, Sanderson RJ, Gordon KA et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*. J Biol Chem 2006; 281 (15): 10540–7. April 14, DOI 10.1074/jbc.M 510026200
11. Katz J, Janik JA, Yones A. Brentuximab vedotin (SGN-35). 2011 Clin Cancer Res 17: 6428–36.
12. Younes A, Gopal AK, Smith SE et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol 2012; 30: 2183–9.
13. Arai S, Fanale M, DeVos S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013; 54: 2531–33.
14. Gopal AK, Chen R, Smith SE et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125 (8): 1236–43.
15. Perrot A, Monjanel H, Bouabdallah R et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica 2014; 99 (s1), 498, abstr S1293.
16. Perrot A, Monjanel H, Bouabdallah R et al. Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica 2016; 101 (4): 466–73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14.
17. Majhail NS, Weisdorf DJ, Defor TE et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065–72.
18. Moskowitz CH, Paszkiewicz-Kozik E, Nadamanee A et al. Analisis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled sdudy of brentuximab vedotin consolidation after autologous stem cell transplant. Hematol Oncol 2015; 33: 165.
19. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. DOI: http://dx.doi.org/10.1016/S0140-6736(15)60165-9. Lancet, Vol. 385, No. 9980, p1853–1862 Published online: March 18, 2015.
20. Sweetenham JW, Walewski J, Nadamanee A et al. Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biol Blood Marrow Transplant 2016; 22: S19e-S481abstr 24.
21. Bonthapally V, Ma E, Viviani S et al. Healthcare utilization in the AETHERA trail: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT. Hematol Oncol 2015; 33: 193, abstr 177.
22. Kuruvilla J, Connors JM, Sawas A et al. A phase 1 study of brentuximab vedotin (BV) and bendamustine (B) in relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL). Hematol Oncol 2015; 33: 148, abstr 090.
23. Theurich S, Malcher J, Wennhold K et al. Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. JCO Feb 10, 2013: e59-e63; published online on December 26, 2012; 10.1200/JCO.2012.43.6832.
________________________________________________
2. Engert A, Younes A, editors. Hematologic malignancies: Hodgkin lymphoma. Second edition. A Comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg: Springer, 2015.
3. Horning S, Fanale M, deVos S et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol 2008; 19: 118(abstr).
4. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14.
5. Matsumoto K, Terakawa M, Miura K et al. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004; 172: 2186–93.
6. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764–9.
7. Forero-Torres A, Leonard JP, Younes A et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146: 171–9.
8. Dosio F, Brusa P, Cattel L. Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins 2011; 3: 848–83.
9. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 2003 102:1458-1465; published ahead of print April 24, 2003 10.1182/blood-2003-01-0039.
10. Kung MS, Sutherland, Sanderson RJ, Gordon KA et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*. J Biol Chem 2006; 281 (15): 10540–7. April 14, DOI 10.1074/jbc.M 510026200
11. Katz J, Janik JA, Yones A. Brentuximab vedotin (SGN-35). 2011 Clin Cancer Res 17: 6428–36.
12. Younes A, Gopal AK, Smith SE et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol 2012; 30: 2183–9.
13. Arai S, Fanale M, DeVos S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013; 54: 2531–33.
14. Gopal AK, Chen R, Smith SE et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125 (8): 1236–43.
15. Perrot A, Monjanel H, Bouabdallah R et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica 2014; 99 (s1), 498, abstr S1293.
16. Perrot A, Monjanel H, Bouabdallah R et al. Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica 2016; 101 (4): 466–73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14.
17. Majhail NS, Weisdorf DJ, Defor TE et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065–72.
18. Moskowitz CH, Paszkiewicz-Kozik E, Nadamanee A et al. Analisis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled sdudy of brentuximab vedotin consolidation after autologous stem cell transplant. Hematol Oncol 2015; 33: 165.
19. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. DOI: http://dx.doi.org/10.1016/S0140-6736(15)60165-9. Lancet, Vol. 385, No. 9980, p1853–1862 Published online: March 18, 2015.
20. Sweetenham JW, Walewski J, Nadamanee A et al. Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biol Blood Marrow Transplant 2016; 22: S19e-S481abstr 24.
21. Bonthapally V, Ma E, Viviani S et al. Healthcare utilization in the AETHERA trail: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT. Hematol Oncol 2015; 33: 193, abstr 177.
22. Kuruvilla J, Connors JM, Sawas A et al. A phase 1 study of brentuximab vedotin (BV) and bendamustine (B) in relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL). Hematol Oncol 2015; 33: 148, abstr 090.
23. Theurich S, Malcher J, Wennhold K et al. Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. JCO Feb 10, 2013: e59-e63; published online on December 26, 2012; 10.1200/JCO.2012.43.6832.
Авторы
Е.А.Демина*
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*drdemina@yandex.ru
N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*drdemina@yandex.ru
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*drdemina@yandex.ru
________________________________________________
N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*drdemina@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.